PRIMECAP Cuts Micron Stake To 18.6 Million Shares — It Remains Its Biggest Holding

Intel and Boston Scientific share counts rose as the disclosed U.S. stock portfolio fell to $161.3 billion.

Share
PRIMECAP Cuts Micron Stake To 18.6 Million Shares — It Remains Its Biggest Holding

PRIMECAP cut its Micron holding to 18.6 million shares from 19.2 million in the third quarter, but the chipmaker remained its largest position. The investment manager's quarterly SEC holdings report, filed Thursday, put the stake at $19.8 billion, about 12% of its disclosed U.S. stock portfolio.

Micron Leads A Smaller Portfolio

PRIMECAP's disclosed U.S. stocks were worth $161.3 billion on September 30, compared with $169.1 billion on June 30. Micron's position value fell from $22.2 billion to $19.8 billion over that period.

The portfolio contained 327 positions, up from 324 in the prior quarter. Its lower total value therefore came alongside a larger number of holdings.

More Intel And Boston Scientific

PRIMECAP increased its Intel holding to 77.3 million shares from 75.3 million. The stake's quarter-end value nevertheless fell to $9.3 billion from $10.5 billion, leaving Intel at about 6% of the portfolio.

Boston Scientific's share count rose to 58.6 million from 50.5 million. The medical-device company's position accounted for about 2% of disclosed holdings.

Microsoft and Nvidia moved in the other direction: PRIMECAP reduced their share counts even as their quarter-end holding values increased. Microsoft fell to 7 million shares from 7.1 million, with the position valued at $3.6 billion; Nvidia fell to 17 million shares from 17.1 million.

Lilly And Alphabet Anchor Existing Bets

PRIMECAP began the quarter with an Eli Lilly stake worth $11 billion, comprising 9.2 million shares. Its Alphabet holding stood at 14.9 million shares valued at $5.3 billion.

Those holdings formed part of an established portfolio in which the third quarter brought adjustments to major positions: fewer Micron, Microsoft and Nvidia shares, and more Intel and Boston Scientific shares.

Sources